Go Pro

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Bayer Aktiengesellschaft stock logo
BAYRY
Bayer Aktiengesellschaft
$14.22
+0.7%
$13.91
$7.48
$15.23
$55.88B0.551.19 million shs346,885 shs
IPSEN stock logo
IPSEY
IPSEN
$49.15
$46.40
$32.02
$51.10
$16.48B0.43262 shs8 shs
Takeda Pharmaceutical Co. stock logo
TAK
Takeda Pharmaceutical
$18.44
+1.1%
$17.15
$12.99
$18.90
$59.07B-0.073.10 million shs1.72 million shs
UCB SA stock logo
UCBJF
UCB
$264.09
+4.7%
$276.71
$225.65
$345.39
$49.92B0.47730 shs389 shs
10 Best Stocks to Own - Summer 2026 Cover

Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Bayer Aktiengesellschaft stock logo
BAYRY
Bayer Aktiengesellschaft
-0.98%-1.53%+1.66%+42.05%+71.78%
IPSEN stock logo
IPSEY
IPSEN
0.00%+3.26%+3.08%+12.09%+44.43%
Takeda Pharmaceutical Co. stock logo
TAK
Takeda Pharmaceutical
+1.28%-0.57%+6.64%+21.41%+21.65%
UCB SA stock logo
UCBJF
UCB
+0.51%-5.68%-6.49%-11.29%+5.49%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Bayer Aktiengesellschaft stock logo
BAYRY
Bayer Aktiengesellschaft
$14.22
+0.7%
$13.91
$7.48
$15.23
$55.88B0.551.19 million shs346,885 shs
IPSEN stock logo
IPSEY
IPSEN
$49.15
$46.40
$32.02
$51.10
$16.48B0.43262 shs8 shs
Takeda Pharmaceutical Co. stock logo
TAK
Takeda Pharmaceutical
$18.44
+1.1%
$17.15
$12.99
$18.90
$59.07B-0.073.10 million shs1.72 million shs
UCB SA stock logo
UCBJF
UCB
$264.09
+4.7%
$276.71
$225.65
$345.39
$49.92B0.47730 shs389 shs
10 Best Stocks to Own - Summer 2026 Cover

Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Bayer Aktiengesellschaft stock logo
BAYRY
Bayer Aktiengesellschaft
-0.98%-1.53%+1.66%+42.05%+71.78%
IPSEN stock logo
IPSEY
IPSEN
0.00%+3.26%+3.08%+12.09%+44.43%
Takeda Pharmaceutical Co. stock logo
TAK
Takeda Pharmaceutical
+1.28%-0.57%+6.64%+21.41%+21.65%
UCB SA stock logo
UCBJF
UCB
+0.51%-5.68%-6.49%-11.29%+5.49%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Bayer Aktiengesellschaft stock logo
BAYRY
Bayer Aktiengesellschaft
3.13
BuyN/AN/A
IPSEN stock logo
IPSEY
IPSEN
2.00
HoldN/AN/A
Takeda Pharmaceutical Co. stock logo
TAK
Takeda Pharmaceutical
2.25
HoldN/AN/A
UCB SA stock logo
UCBJF
UCB
2.75
Moderate BuyN/AN/A

Current Analyst Ratings Breakdown

Latest IPSEY, TAK, BAYRY, and UCBJF Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/4/2026
Takeda Pharmaceutical Co. stock logo
TAK
Takeda Pharmaceutical
UpgradeStrong SellHold
8/3/2026
UCB SA stock logo
UCBJF
UCB
UpgradeHold
8/2/2026
IPSEN stock logo
IPSEY
IPSEN
DowngradeHoldModerate Sell
7/30/2026
Takeda Pharmaceutical Co. stock logo
TAK
Takeda Pharmaceutical
DowngradeHold (C-)Sell (D+)
7/22/2026
UCB SA stock logo
UCBJF
UCB
Reiterated RatingNeutral
7/10/2026
Bayer Aktiengesellschaft stock logo
BAYRY
Bayer Aktiengesellschaft
UpgradeHoldStrong-Buy
7/2/2026
Bayer Aktiengesellschaft stock logo
BAYRY
Bayer Aktiengesellschaft
UpgradeHoldBuy
6/30/2026
IPSEN stock logo
IPSEY
IPSEN
Reiterated RatingBuy
6/29/2026
Takeda Pharmaceutical Co. stock logo
TAK
Takeda Pharmaceutical
DowngradeHoldStrong Sell
6/23/2026
Takeda Pharmaceutical Co. stock logo
TAK
Takeda Pharmaceutical
DowngradeHold (C)Hold (C-)
6/5/2026
IPSEN stock logo
IPSEY
IPSEN
Initiated CoverageBuy
(Data available from 9/2/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Bayer Aktiengesellschaft stock logo
BAYRY
Bayer Aktiengesellschaft
$51.55B1.08$2.18 per share6.53$7.50 per share1.90
IPSEN stock logo
IPSEY
IPSEN
$4.16B3.96$5.51 per share8.92$14.64 per share3.36
Takeda Pharmaceutical Co. stock logo
TAK
Takeda Pharmaceutical
$4.62T0.01$3.18 per share5.79$14.86 per share1.24
UCB SA stock logo
UCBJF
UCB
$5.27B9.48$11.34 per share23.28$50.52 per share5.23
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Bayer Aktiengesellschaft stock logo
BAYRY
Bayer Aktiengesellschaft
-$4.10B-$0.51N/A10.614.46-3.80%17.00%4.55%11/3/2026 (Estimated)
IPSEN stock logo
IPSEY
IPSEN
$501.78MN/AN/A12.38N/AN/AN/AN/AN/A
Takeda Pharmaceutical Co. stock logo
TAK
Takeda Pharmaceutical
-$1.01B$0.3454.2214.18N/A3.80%10.95%5.34%10/29/2026 (Estimated)
UCB SA stock logo
UCBJF
UCB
$371.23MN/AN/A37.41N/AN/AN/AN/AN/A

Latest IPSEY, TAK, BAYRY, and UCBJF Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/4/2026Q2 2026
Bayer Aktiengesellschaft stock logo
BAYRY
Bayer Aktiengesellschaft
$0.23$0.29+$0.06$0.07$12.31 billion$12.53 billion
7/30/2026Q1 2027
Takeda Pharmaceutical Co. stock logo
TAK
Takeda Pharmaceutical
$0.41$0.95+$0.54$0.22$7.13 billion$7.50 billion
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Bayer Aktiengesellschaft stock logo
BAYRY
Bayer Aktiengesellschaft
$0.020.14%N/AN/A N/A
IPSEN stock logo
IPSEY
IPSEN
$0.300.61%N/AN/AN/A
Takeda Pharmaceutical Co. stock logo
TAK
Takeda Pharmaceutical
$0.482.60%-6.89%141.18%N/A
UCB SA stock logo
UCBJF
UCB
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Bayer Aktiengesellschaft stock logo
BAYRY
Bayer Aktiengesellschaft
1.06
1.05
0.70
IPSEN stock logo
IPSEY
IPSEN
N/A
1.96
1.79
Takeda Pharmaceutical Co. stock logo
TAK
Takeda Pharmaceutical
0.58
1.14
0.62
UCB SA stock logo
UCBJF
UCB
0.33
1.19
0.78

Institutional Ownership

CompanyInstitutional Ownership
Bayer Aktiengesellschaft stock logo
BAYRY
Bayer Aktiengesellschaft
N/A
IPSEN stock logo
IPSEY
IPSEN
N/A
Takeda Pharmaceutical Co. stock logo
TAK
Takeda Pharmaceutical
9.17%
UCB SA stock logo
UCBJF
UCB
N/A

Insider Ownership

CompanyInsider Ownership
Bayer Aktiengesellschaft stock logo
BAYRY
Bayer Aktiengesellschaft
N/A
IPSEN stock logo
IPSEY
IPSEN
N/A
Takeda Pharmaceutical Co. stock logo
TAK
Takeda Pharmaceutical
0.04%
UCB SA stock logo
UCBJF
UCB
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
Bayer Aktiengesellschaft stock logo
BAYRY
Bayer Aktiengesellschaft
88,0783.93 billionN/ANot Optionable
IPSEN stock logo
IPSEY
IPSEN
5,535335.26 millionN/ANot Optionable
Takeda Pharmaceutical Co. stock logo
TAK
Takeda Pharmaceutical
47,0003.20 billion3.20 billionOptionable
UCB SA stock logo
UCBJF
UCB
9,083189.02 millionN/ANot Optionable

Recent News About These Companies

UCB assumed with an Underperform at Jefferies
UCB SA (UCBJF) Q2 2025 Earnings Call Transcript

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Bayer Aktiengesellschaft stock logo

Bayer Aktiengesellschaft OTCMKTS:BAYRY

$14.22 +0.10 (+0.71%)
As of 03:59 PM Eastern

Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and digital solutions, and contrast agents, as well as cell and gene therapy. The Consumer Health segment markets nonprescription over-the-counter medicines for self-medication and self-care; and solutions for nutritional supplements, allergy, cough and cold, dermatology, pain and cardiovascular risk prevention, and digestive health. This segment also provides breeding, propagation, and production/processing of seeds, including seed dressing. The company has a collaboration with Acuitas Therapeutics, Inc. to strengthen gene editing programs; Peking University in the area of basic pharmaceutical research; the Swiss Tropical and Public Health Institute in the development of the compound emodepside for the treatment of infection with soil-transmitted helminths; bit.bio Ltd. for the discovery and manufacture of regulatory T cells for use in creating therapeutics; Hologic, Inc. in the field of contrastenhanced-mammography solutions to improve diagnostic imaging for the detection of breast cancer; and Twist Bioscience Corporation centering around the research and development of antibody-based pharmaceuticals, as well as with CrossBay Medical Inc. It distributes its products through wholesalers, pharmacies and pharmacy chains, supermarkets, online and other retailers, and hospitals, as well as directly to farmers. The company has collaboration with Thermo Fisher Scientific. Bayer Aktiengesellschaft was founded in 1863 and is based in Leverkusen, Germany.

IPSEN stock logo

IPSEN OTCMKTS:IPSEY

$49.15 0.00 (0.00%)
As of 09/1/2026

Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, and rare diseases. Its product pipeline comprises Cabometyx + Atezolizumab, which is in phase III clinical trial for the treatment of second line metastatic castration-resistant prostate cancer; lenalidomide and rituximab, and Taverik, which is in phase III for the treatment of second line follicular lymphoma; Bylvay, which is in phase III for the treatment of biliary atresia; Dysport, which is in phase III clinical trial for the treatment of chronic and episodic migraine; Fidrisertib, which is in phase II clinical trial for the treatment of fibrodysplasia ossificans progressiva; Elafibranor, which is in phase II for the treatment of primary sclerosing cholangitis, as well as IPN60250; IPN10200, which is in phase II for the treatment of longer-acting neurotoxin aesthetics and therapeutics; IPN60210, which is in phase I clinical trial for the treatment of relapsed/refractory multiple myeloma; and IPN60260 for the treatment of Viral cholestatic disease and is in phase I clinical trial. The company also offers Somatuline, Decapeptyl, Cabometyx, Onivyde, Tazverik, and other oncology products; Dysport and other neurosciences products; and Bylvay, NutropinAq, Increlex, and Sohonos for rare diseases. The company was founded in 1929 and is based in Boulogne-Billancourt, France.

Takeda Pharmaceutical stock logo

Takeda Pharmaceutical NYSE:TAK

$18.43 +0.21 (+1.12%)
Closing price 03:59 PM Eastern
Extended Trading
$18.06 -0.38 (-2.03%)
As of 05:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba, Recombinate, Hemofil/Immunate/Immunine, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Flexbumin, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Ninlaro, Velcade, Azilva-F, Lotriga, Iclusig, Leuplin/Enantone, Adcetris, vyvanse/elvanse, Trintellix, and Alunbrig brands. It has in-license agreement with BioMarin, Luxna Biotech, GlaxoSmithKline, Halozyme, and Kamada; collaboration with Neurocrine Biosciences, Inc., Seagen Inc., Anima Biotech, Denali Therapeutics, KSQ Therapeutics, Noile-Immune Biotech, Center for iPS Cell Research Application, Kyoto University (CiRA), and Charles River Laboratories; licensing agreement with Mirum Pharmaceuticals and Twist Bioscience, UCSD/Fortis Advisors, PeptiDream, MD Anderson Cancer Center, Teva Pharmaceutical Industries, and Xenetic Biosciences; collaboration and licensing agreement with Arrowhead Pharmaceuticals Inc., Engitix, Genevant Sciences Corporation, Sosei Heptares, Zedira/Dr. Falk Pharma, Exelixis, Inc., GlaxoSmithKline, Heidelberg Pharma, HUTCHMED, Presage Biosciences, Codexis, Inc., Ensoma, Envozyne, KM Biologics, and Selecta BioScience, and Ovid Therapeutics Inc.; and collaboration with ZEDIRA GmbH and Dr. Falk Pharma GmbH. It has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, and Selecta Biosciences. The company was founded in 1781 and is headquartered in Tokyo, Japan.

UCB stock logo

UCB OTCMKTS:UCBJF

$264.09 +11.93 (+4.73%)
As of 03:35 PM Eastern

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies. It also offers Evenity for the treatment of osteoporosis in postmenopausal women; Bimzelx for treating plaque psoriasis, psoriatic arthritis, and axial spondyloarthritis; and Fintepla to treat Dravet syndrome. In addition, the company is involved in developing rozanolixizumab and Zilbrisq to treat myasthenia gravis; dapirolizumab pegol for systemic lupus erythematosus; fenfluramine to treat CDKL5 deficiency disorder; doxecitine for TK2 deficiency disorder; STACCATO alprazolam for stereotypical prolonged seizures; bepranemab to treat Alzheimer's disease; minzasolmin and UCB0222 for Parkinson's disease; and UCB1381 and UCB9741 for atropic dermatitis. Further, it engages in contract manufacturing activities. UCB SA has collaboration agreements with Amgen, Biogen, Roche/Genentech, Novartis, and Otsuka. The company was incorporated in 1925 and is headquartered in Brussels, Belgium.